InflaRx (IFRX) Share-based Compensation (2017 - 2026)
InflaRx's (IFRX) quarterly Share-based Compensation came in at $687392.9 in Q2 2026, down 45.22% year-over-year from $1.3 million in Q2 2025, and down 37.61% quarter-over-quarter from $1.1 million in Q1 2026.
Analysis
InflaRx (IFRX) Share-based Compensation (2017 - 2026) Analysis & Trends
InflaRx has disclosed Share-based Compensation across 10 years of filings, most recently posting $687392.9 for Q2 2026.
- In Q2 2026, Share-based Compensation fell 45.22% year-over-year to $687392.9; the TTM figure through Jun 2026 stood at $2.8 million (down 43.58% YoY), while the FY2025 annual figure was $5.0 million, up 15.58% from the prior year.
- Share-based Compensation came in at $687392.9 for Q2 2026 at InflaRx, down from $1.1 million in the prior quarter.
- In the past five years, Share-based Compensation ranged from a high of $2.8 million in Q1 2022 to a low of $302937.7 in Q4 2025.
- Average Share-based Compensation over 5 years is $1.2 million, with a median of $1.0 million recorded in 2022.
- Year-over-year, Share-based Compensation surged 95.98% in 2022 and tumbled 57.76% in 2026.
- Over 5 years, Share-based Compensation stood at $472716.3 in 2022, then climbed by 3.11% to $487398.6 in 2023, then retreated by 25.48% to $363215.6 in 2024, then retreated by 16.6% to $302937.7 in 2025, then soared by 126.91% to $687392.9 in 2026.
- Per Business Quant data, the three most recent Share-based Compensation figures were $687392.9 in Q2 2026, $1.1 million in Q1 2026, and $302937.7 in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 247.00 Mn |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | 231.00 Mn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | 108.10 Mn |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 243.00 Mn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | - |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | 120.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 86.63 Mn |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | 77.40 Mn |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | 83.34 Mn |
| 10 | InflaRx | 139.29 Mn | -44.96 Mn | 2.74 Mn | 687,392.90 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 687,392.90 |
| Mar 31, 2026 | 1.10 Mn |
| Dec 31, 2025 | 302,937.67 |
| Sep 30, 2025 | 696,615.38 |
| Jun 30, 2025 | 1.25 Mn |
| Mar 31, 2025 | 2.61 Mn |
| Dec 31, 2024 | 363,215.58 |
| Sep 30, 2024 | 716,142.35 |
| Jun 30, 2024 | 1.31 Mn |
| Mar 31, 2024 | 2.02 Mn |
| Dec 31, 2023 | 487,398.63 |
| Sep 30, 2023 | 786,064.65 |
| Jun 30, 2023 | 1.12 Mn |
| Mar 31, 2023 | 1.30 Mn |
| Dec 31, 2022 | 472,716.31 |
| Sep 30, 2022 | 920,090.66 |
| Jun 30, 2022 | 2.28 Mn |
| Mar 31, 2022 | 2.84 Mn |
| Dec 31, 2021 | 581,838.50 |
| Sep 30, 2021 | 1.34 Mn |